MLLT3 and acute myeloid leukemia: Correspondingly, an RAR antagonist decreased LSC-related properties in an Evi1-dependent manner in vitro and in vivo, and prolonged survival of both of primary treated and secondary recipient mice with Evi1high, MLL-AF9-driven AML.